英国疫苗网络:映射流行潜力的优先病原体与疫苗管线进展
2013–2016年西非埃博拉疫情期间,英国首相指示成立专家组识别未来可能引起流行病的优先病原体,共确定13种优先病原体,并据此优先资助新发疾病疫苗研发。本会议报告总结了英国优先病原体清单的制定过程,与其他机构清单比较,并概述针对优先疾病疫苗的临床进展;疫苗研发有明确技术进展,但可用性取决于流行间期持续资助临床试验和制备临床可接受材料。
要点
- 英国基于2013–2016年西非埃博拉疫情成立专家组,确定13种优先病原体。
- 该清单推动英国在新发疾病疫苗研发上的经费优先投入。
- 疫苗研发有明确技术进展,但可用性依赖流行间期持续资助临床试验与制备临床可接受材料。
核心结论
- 针对优先病原体的疫苗研发已有明确技术进展,但其可用性取决于流行间期持续资助临床试验和制备临床可接受材料。
研究设计与样本
- 会议报告,总结英国优先病原体清单制定过程,并与其他机构清单比较及概述疫苗临床进展。
- 专家组按英国首相指示成立,共确定13种优先病原体。
主要发现
- 英国确定13种优先病原体,并据此优先资助新发疾病疫苗研发。
- 报告比较了英国清单与世界卫生组织、美国国家过敏和传染病研究所清单。
- 报告总结了针对优先疾病疫苗开发的临床进展。
临床怎么用
- 可参考英国优先病原体清单制定流程,用于疫苗研发优先级设置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the 2013-2016 Ebola outbreak in West Africa an expert panel was established on the instructions of the UK Prime Minister to identify priority pathogens for outbreak diseases that had the potential to cause future epidemics. A total of 13 priority pathogens were identified, which led to the prioritisation of spending in emerging diseases vaccine research and development from the UK. This meeting report summarises the process used to develop the UK pathogen priority list, compares it to lists generated by other organisations (World Health Organisation, National Institutes of Allergy and Infectious Diseases) and summarises clinical progress towards the development of vaccines against priority diseases. There is clear technical progress towards the development of vaccines. However, the availability of these vaccines will be dependent on sustained funding for clinical trials and the preparation of clinically acceptable manufactured material during inter-epidemic periods.
引用
- Noad RJ, Simpson K, Fooks AR, et al. UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. Vaccine. 2019. PMID: 31522809. doi:10.1016/j.vaccine.2019.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。